• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply to comment on "Adjuvant S-1 vs gemcitabine for node-positive perihilar cholangiocarcinoma".

作者信息

Takahashi Daigoro, Mizuno Takashi, Ebata Tomoki

机构信息

Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Aichi, Japan.

出版信息

J Hepatobiliary Pancreat Sci. 2022 Apr;29(4):e29. doi: 10.1002/jhbp.1070. Epub 2021 Nov 8.

DOI:10.1002/jhbp.1070
PMID:34748277
Abstract
摘要

相似文献

1
Reply to comment on "Adjuvant S-1 vs gemcitabine for node-positive perihilar cholangiocarcinoma".对“辅助性S-1与吉西他滨治疗淋巴结阳性肝门周围胆管癌”评论的回复
J Hepatobiliary Pancreat Sci. 2022 Apr;29(4):e29. doi: 10.1002/jhbp.1070. Epub 2021 Nov 8.
2
Comment on "Adjuvant S-1 vs gemcitabine for node-positive perihilar cholangiocarcinoma".关于“辅助性S-1与吉西他滨治疗淋巴结阳性肝门部胆管癌的比较”的评论
J Hepatobiliary Pancreat Sci. 2022 Apr;29(4):e28. doi: 10.1002/jhbp.1072. Epub 2021 Nov 8.
3
Adjuvant S-1 vs gemcitabine for node-positive perihilar cholangiocarcinoma: A propensity score-adjusted analysis.辅助 S-1 对比吉西他滨治疗淋巴结阳性肝门部胆管癌：一项倾向评分调整分析。
J Hepatobiliary Pancreat Sci. 2021 Sep;28(9):716-726. doi: 10.1002/jhbp.1005. Epub 2021 Jun 22.
4
Complete response of recurrent perihilar cholangiocarcinoma following sintilimab combined with lenvatinib plus S-1: a case report and review of literature.信迪利单抗联合仑伐替尼加替吉奥治疗复发性肝门部胆管癌完全缓解 1 例报告并文献复习
Anticancer Drugs. 2024 Jan 1;35(1):81-85. doi: 10.1097/CAD.0000000000001519. Epub 2023 Apr 28.
5
Reply: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial.回复：吉西他滨联合顺铂与卡培他滨用于淋巴结阳性肝外胆管癌辅助治疗的比较：STAMP随机试验
Hepatology. 2023 Oct 1;78(4):E74-E75. doi: 10.1097/HEP.0000000000000535. Epub 2023 Jul 17.
6
Efficacy and safety of systemic induction therapy in initially unresectable locally advanced intrahepatic and perihilar cholangiocarcinoma: A systematic review.系统诱导治疗对初始不可切除的局部进展期肝内和肝门周围胆管癌的疗效和安全性：系统评价。
Cancer Treat Rev. 2020 Dec;91:102110. doi: 10.1016/j.ctrv.2020.102110. Epub 2020 Oct 6.
7
Reply to comment on "surgical implications of the confluence patterns of the left intrahepatic bile ducts in right hepatectomy for perihilar cholangiocarcinoma".对“肝门部胆管癌右半肝切除术中左肝内胆管汇合模式的手术意义”一文评论的回复
J Hepatobiliary Pancreat Sci. 2023 Feb;30(2):e7-e8. doi: 10.1002/jhbp.1226. Epub 2022 Aug 17.
8
Letter to the Editor: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial.致编辑的信：吉西他滨联合顺铂与卡培他滨用于淋巴结阳性肝外胆管癌的辅助治疗：STAMP随机试验
Hepatology. 2023 Oct 1;78(4):E72-E73. doi: 10.1097/HEP.0000000000000532. Epub 2023 Jul 17.
9
[Long-Term Survival after Surgery with Postoperative Chemotherapy for Perihilar Cholangiocarcinoma with Residual Invasive Carcinoma at Ductal Resection Margins-A Case Report].[肝门部胆管癌手术切除胆管切缘残留浸润癌术后化疗的长期生存——病例报告]
Gan To Kagaku Ryoho. 2020 Dec;47(13):1899-1901.
10
Repetitive response to gemcitabine that led to curative resection in cholangiocarcinoma.吉西他滨重复治疗反应致使胆管癌得以根治性切除。
World J Gastroenterol. 2009 Sep 28;15(36):4593-5. doi: 10.3748/wjg.15.4593.